BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1567 related articles for article (PubMed ID: 28530702)

  • 1. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug.
    Wu H; Esteve E; Tremaroli V; Khan MT; Caesar R; Mannerås-Holm L; Ståhlman M; Olsson LM; Serino M; Planas-Fèlix M; Xifra G; Mercader JM; Torrents D; Burcelin R; Ricart W; Perkins R; Fernàndez-Real JM; Bäckhed F
    Nat Med; 2017 Jul; 23(7):850-858. PubMed ID: 28530702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined effects of
    Shin NR; Gu N; Choi HS; Kim H
    Am J Physiol Endocrinol Metab; 2020 Jan; 318(1):E52-E61. PubMed ID: 31770016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Relationship between the Gut Microbiome and Metformin as a Key for Treating Type 2 Diabetes Mellitus.
    Lee CB; Chae SU; Jo SJ; Jerng UM; Bae SK
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota.
    Forslund K; Hildebrand F; Nielsen T; Falony G; Le Chatelier E; Sunagawa S; Prifti E; Vieira-Silva S; Gudmundsdottir V; Pedersen HK; Arumugam M; Kristiansen K; Voigt AY; Vestergaard H; Hercog R; Costea PI; Kultima JR; Li J; Jørgensen T; Levenez F; Dore J; ; Nielsen HB; Brunak S; Raes J; Hansen T; Wang J; Ehrlich SD; Bork P; Pedersen O
    Nature; 2015 Dec; 528(7581):262-266. PubMed ID: 26633628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut.
    de la Cuesta-Zuluaga J; Mueller NT; Corrales-Agudelo V; Velásquez-Mejía EP; Carmona JA; Abad JM; Escobar JS
    Diabetes Care; 2017 Jan; 40(1):54-62. PubMed ID: 27999002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin: old friend, new ways of action-implication of the gut microbiome?
    Rodriguez J; Hiel S; Delzenne NM
    Curr Opin Clin Nutr Metab Care; 2018 Jul; 21(4):294-301. PubMed ID: 29634493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities.
    Brunkwall L; Orho-Melander M
    Diabetologia; 2017 Jun; 60(6):943-951. PubMed ID: 28434033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Gut Microbiome, Metformin, and Aging.
    Induri SNR; Kansara P; Thomas SC; Xu F; Saxena D; Li X
    Annu Rev Pharmacol Toxicol; 2022 Jan; 62():85-108. PubMed ID: 34449247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjunctive Probio-X Treatment Enhances the Therapeutic Effect of a Conventional Drug in Managing Type 2 Diabetes Mellitus by Promoting Short-Chain Fatty Acid-Producing Bacteria and Bile Acid Pathways.
    Chen Y; Shen X; Ma T; Yu X; Kwok LY; Li Y; Sun Z; Li D; Zhang H
    mSystems; 2023 Feb; 8(1):e0130022. PubMed ID: 36688679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Non-insulin Anti-hyperglycemic Agents on Gut Microbiota: A Systematic Review on Human and Animal Studies.
    Cao TTB; Wu KC; Hsu JL; Chang CS; Chou C; Lin CY; Liao YM; Lin PC; Yang LY; Lin HW
    Front Endocrinol (Lausanne); 2020; 11():573891. PubMed ID: 33071980
    [No Abstract]   [Full Text] [Related]  

  • 11. Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study.
    Bryrup T; Thomsen CW; Kern T; Allin KH; Brandslund I; Jørgensen NR; Vestergaard H; Hansen T; Hansen TH; Pedersen O; Nielsen T
    Diabetologia; 2019 Jun; 62(6):1024-1035. PubMed ID: 30904939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclocarya paliurus polysaccharides alleviate type 2 diabetic symptoms by modulating gut microbiota and short-chain fatty acids.
    Yao Y; Yan L; Chen H; Wu N; Wang W; Wang D
    Phytomedicine; 2020 Oct; 77():153268. PubMed ID: 32663709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of gut microbiota in obesity, diabetes mellitus, and effect of metformin: new insights into old diseases.
    Pascale A; Marchesi N; Govoni S; Coppola A; Gazzaruso C
    Curr Opin Pharmacol; 2019 Dec; 49():1-5. PubMed ID: 31015106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin.
    Sun L; Xie C; Wang G; Wu Y; Wu Q; Wang X; Liu J; Deng Y; Xia J; Chen B; Zhang S; Yun C; Lian G; Zhang X; Zhang H; Bisson WH; Shi J; Gao X; Ge P; Liu C; Krausz KW; Nichols RG; Cai J; Rimal B; Patterson AD; Wang X; Gonzalez FJ; Jiang C
    Nat Med; 2018 Dec; 24(12):1919-1929. PubMed ID: 30397356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A specific gut microbiota and metabolomic profiles shifts related to antidiabetic action: The similar and complementary antidiabetic properties of type 3 resistant starch from Canna edulis and metformin.
    Zhang C; Ma S; Wu J; Luo L; Qiao S; Li R; Xu W; Wang N; Zhao B; Wang X; Zhang Y; Wang X
    Pharmacol Res; 2020 Sep; 159():104985. PubMed ID: 32504839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic modelling of the human gut microbiome in type 2 diabetes patients in response to metformin treatment.
    Ezzamouri B; Rosario D; Bidkhori G; Lee S; Uhlen M; Shoaie S
    NPJ Syst Biol Appl; 2023 Jan; 9(1):2. PubMed ID: 36681701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes.
    van Bommel EJM; Herrema H; Davids M; Kramer MHH; Nieuwdorp M; van Raalte DH
    Diabetes Metab; 2020 Apr; 46(2):164-168. PubMed ID: 31816432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considering gut microbiota in treatment of type 2 diabetes mellitus.
    Adeshirlarijaney A; Gewirtz AT
    Gut Microbes; 2020 May; 11(3):253-264. PubMed ID: 32005089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolites Linking the Gut Microbiome with Risk for Type 2 Diabetes.
    Zhu T; Goodarzi MO
    Curr Nutr Rep; 2020 Jun; 9(2):83-93. PubMed ID: 32157661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats.
    Zhang M; Feng R; Yang M; Qian C; Wang Z; Liu W; Ma J
    BMJ Open Diabetes Res Care; 2019; 7(1):e000717. PubMed ID: 31641523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 79.